Neoadjuvant intetamab in combination with standard chemotherapy for locally advanced HER2-positive breast cancer

被引：0
|
作者：
Jiang, M. [1 ]
Chai, Y. [1 ]
Liu, J. [2 ]
He, M. [1 ]
Zhang, M. [1 ]
Zhou, S. [1 ]
Xu, B. [3 ]
Li, Q. [2 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Med Oncol, Canc Hosp, Beijing, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Med Oncol, Canc Hosp, Beijing, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.270
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
331P
引用
收藏
页码：S353 / S353
页数：1
相关论文
共 50 条
  • [1] Surgery following neoadjuvant chemotherapy for HER2-positive locally advanced breast cancer. Time to reconsider the standard attitude
    Debled, Marc
    MacGrogan, Gaetan
    Breton-Callu, Christelle
    Ferron, Stephane
    Hurtevent, Gabrielle
    Fournier, Marion
    Bourdarias, Lionel
    Bonnefoi, Herve
    Mauriac, Louis
    de Lara, Christine Tunon
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (06) : 697 - 704
  • [2] Evolution of neoadjuvant chemotherapy (NAC) in locally advanced HER2-positive breast cancer over 10 years in Hong Kong
    Chiu, J. W. Y.
    Leung, R.
    Tang, V.
    Cheuk, I.
    Lo, J.
    Wong, H.
    Kwok, G.
    Suen, D.
    Yau, T.
    Kwong, A.
    ANNALS OF ONCOLOGY, 2015, 26 : 22 - 22
  • [3] Neoadjuvant chemotherapy for triple-negative and HER2-positive breast cancer: Striving for the standard of care
    Roberts, Amanda
    Coburn, Natalie
    Wright, Frances
    Nguyen, Lena
    Gandhi, Sonal
    Hallet, Julie
    Jerzak, Katarzyna
    Eisen, Andrea
    Wilton, Andrew
    Hong, Nicole Look
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (SUPPL 1) : 199 - 200
  • [4] Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis
    Debiasi, Marcio
    Polanczyk, Carisi A.
    Ziegelmann, Patricia
    Barrios, Carlos
    Cao, Hongyuan
    Dignam, James J.
    Goss, Paul
    Bychkovsky, Brittany
    Finkelstein, Dianne M.
    Guindalini, Rodrigo S.
    Filho, Paulo
    Albuquerque, Caroline
    Reinert, Tomas
    de Azambuja, Evandro
    Olopade, Olufunmilayo
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [5] Neoadjuvant pembrolizumab plus decitabine followed by standard neoadjuvant chemotherapy for locally advanced HER2-breast cancer
    Bear, Harry Douglas
    Idowu, Michael O.
    Poklepovic, Andrew
    Sima, Adam
    Kmieciak, Maciej
    CANCER RESEARCH, 2020, 80 (04)
  • [6] The Efficacy of Neoadjuvant Chemotherapy for HER-2-Positive Locally Advanced Breast Cancer and Survival Analysis
    Zhang, Wei
    Tian, Huan
    Yang, Shi-hong
    ANALYTICAL CELLULAR PATHOLOGY, 2017, 2017
  • [7] Neoadjuvant chemotherapy in HER2-positive and triple-negative breast cancer
    Goncalves, Anthony
    BULLETIN DU CANCER, 2016, 103 (06) : S76 - S89
  • [8] Neoadjuvant chemotherapy with or without anthracyclines in combination with single HER2-targeted therapy in HER2-positive breast cancer
    Gupta, Anshul
    Gogia, Ajay
    Deo, S. V. S.
    Sharma, D. N.
    Mathur, Sandip
    Sagiraju, Hari Krishna Raju
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2023, 36
  • [9] Neoadjuvant Trastuzumab and Pertuzumab in Combination with Standard Chemotherapy for HER2-Positive Early Breast Cancer: Real-World Practice in Cuba
    Medina, Elias A. Gracia
    Caballero, Brenda Benitez
    Miguel, Karen Lopez
    Gutierrez, Zaili Aleaga
    Fernandez, Braulio Mestre
    Tul, Luis E. Alsina
    Rodriguez, Luis E. Martin
    Guerrero, Orlando Valdes
    Varela, Idania G. Sanchez
    Bernardo, Maria de la Caridad Campos
    Montero, Yoandri Calderon
    Ortiz, Monica Ramos
    Carrasco, Julien Martinez
    Torres, Keytia Pena
    Prado, Yenia I. Diaz
    Rubio, Maria Caridad
    Braojo, Ines M. Perez
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2023, 34
  • [10] An exploratory study of Trastuzumab Deruxtecan neoadjuvant therapy in HER2-positive or HER2-low early or locally advanced breast cancer after a poor response to neoadjuvant chemotherapy
    Zhang, Jin
    Shi, Zhendong
    Liu, Jingjing
    CANCER RESEARCH, 2024, 84 (09)
12345